Aktis Oncology, Inc.(AKTS)
$17.04-0.41 (-2.35%)
AKTS
Aktis Oncology, Inc. stock forecast
$17.04
At close:-0.41 (-2.35%)
Want to see AKTS full AI Analyst Report?
Aktis Oncology, Inc. (AKTS) Stock Forecast & Price Target
42 Followers
AKTS Analyst Ratings
Strong Buy
6Buy0Hold0Sell
Based on 6 analysts giving stock ratings to Aktis Oncology, Inc. in the past 3 months
AKTS Stock 12 Month Forecast
Average Price Target
$35.80▲(110.09% Upside)Based on 6 Wall Street analysts offering 12 month price targets for Aktis Oncology, Inc. in the last 3 months. The average price target is $35.80 with a high forecast of $40.00 and a low forecast of $33.00. The average price target represents a 110.09% change from the last price of $17.04.
Past 12 Months12 Month ForecastJan2026Oct2026
High$40.00
Average$35.80
Low$33.00
Highest Price TargetHighest$40.00Average Price Target$35.80Lowest Price TargetLowest$33.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| David Nierengarten | Wedbush | $35 | buy | 105.40%Upside | Reiterated | 10/02/26 | ||
| Jeff Jones | Oppenheimer | $40 | buy | 134.74%Upside | Initiated | 09/09/26 | ||
| David Lebowitz | BMO Capital | $37 | buy | 117.14%Upside | Initiated | 08/18/26 | ||
| Alexandra Ramsey | William Blair | ― | buy | ― | Reiterated | 08/14/26 | ||
| Jessica Fye | J.P. Morgan | $33 | buy | 93.66%Upside | Assigned | 08/14/26 | ||
| Alec Stranahan | Bank of America Securities | $34 | buy | 99.53%Upside | Reiterated | 08/14/26 | ||
| Christopher Raymond | Raymond James | $40 | buy | 134.74%Upside | Initiated | 06/16/26 | ||
| Robert Burns | H.C. Wainwright | $35 | buy | 105.40%Upside | Assigned | 06/03/26 | ||
| Tyler Van Buren | TD Cowen | ― | buy | ― | Reiterated | 05/11/26 | ||
| Jonathan Chang | Leerink Partners | $31 | buy | 81.92%Upside | Initiated | 02/03/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| David NierengartenWedbush | BuyReiterated$35 | 10/02/26 | 105.40%Upside | ||
| Jeff JonesOppenheimer | BuyInitiated$40 | 09/09/26 | 134.74%Upside | ||
| David LebowitzBMO Capital | BuyInitiated$37 | 08/18/26 | 117.14%Upside | ||
| Alexandra RamseyWilliam Blair | BuyReiterated | 08/14/26 | ― | ||
| Jessica FyeJ.P. Morgan | BuyAssigned$33 | 08/14/26 | 93.66%Upside | ||
| Alec StranahanBank of America Securities | BuyReiterated$34 | 08/14/26 | 99.53%Upside | ||
| Christopher RaymondRaymond James | BuyInitiated$40 | 06/16/26 | 134.74%Upside | ||
| Robert BurnsH.C. Wainwright | BuyAssigned$35 | 06/03/26 | 105.40%Upside | ||
| Tyler Van BurenTD Cowen | BuyReiterated | 05/11/26 | ― | ||
| Jonathan ChangLeerink Partners | BuyInitiated$31 | 02/03/26 | 81.92%Upside |
Stocks with the Highest Top Analyst Consensus in the General Sector
Best Analysts Covering Aktis Oncology, Inc.
3 Months
Success Rate2/3 ratings generated profit
67%
Average Return
+41.10%
Copying Tyler Van Buren's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +41.10% per trade.
1 Year
Success Rate1/3 ratings generated profit
33%
Average Return
-1.97%
Copying PerPlexity Biotechnology's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -1.97% per trade.
2 Years
Success Rate1/3 ratings generated profit
33%
Average Return
-1.97%
Copying PerPlexity Biotechnology's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -1.97% per trade.
AKTS Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 6 | 2 | 1 | 2 | 2 |
| Buy | 8 | 8 | 7 | 5 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 14 | 10 | 8 | 7 | 2 |
In the current month, AKTS has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AKTS average Analyst price target in the past 3 months is 35.80.
AKTS Financial Forecast
AKTS Stock Forecast FAQ
What is AKTS’s average 12-month price target, according to analysts?
Based on analyst ratings, Aktis Oncology, Inc.’s 12-month average price target is $35.80.
What is AKTS’s upside potential, based on the analysts’ average price target?
Aktis Oncology, Inc. has 110.09% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is AKTS a Buy, Sell or Hold?
Aktis Oncology, Inc. has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is Aktis Oncology, Inc.’s price target?
The average price target for Aktis Oncology, Inc. is $35.80. This is based on 6 12-month price targets, issued in the past 3 months. The highest analyst price target is $40.00, the lowest forecast is $33.00. The average price target represents a 110.09% increase from the current price of $17.04.
What do analysts say about Aktis Oncology, Inc.?
Aktis Oncology, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Street analysts.
How can I buy shares of AKTS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
